# Nephrology Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ida B. Wells (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET022-SYN-TD
- Date: 1931-01-05
- Fictional facility: St. Posthumous Health Center
- Fictional author: Cordelia Ashworth-Banks, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- To: Emeka Lindqvist-Moore, MD, Nephrology
- Urgency: Within two weeks, on the day of her two-week visit, after the repeat urine test and the kidney ultrasound

## Referral question

New chronic kidney disease, probably G3b A2, of uncertain cause in a 68-year-old Black woman with tiredness, ankle swelling and high blood pressure readings: race-free eGFR 40 by creatinine and 38 with cystatin C, and a urine albumin-to-creatinine ratio of 240 mg/g. Please advise on the cause and further evaluation, APOL1 genetic testing, kidney-protective treatment and its order, the anemia and mineral findings, and how and when to plan for the future. **S**

## Questions for the consultant

1. What is the most likely cause of her kidney disease, and does she need further tests, including a kidney biopsy?
2. Do you agree with the race-free staging, and how should we use cystatin C from here?
3. Should she be offered APOL1 genetic testing, and how would a result change her care?
4. Which kidney-protective medicines do you advise, in what order, and with what blood pressure target?
5. How should we manage the mild anemia, the low vitamin D and the raised PTH?
6. How often should she be seen by nephrology, and when should planning for kidney replacement begin?

## Pertinent history

Mrs. Wells is a journalist and civic leader, active and independent, who has been tired for some months and notices ankle swelling by evening. She has taken over-the-counter naproxen for knee aching for about a year; it was stopped today. She has no diabetes symptoms, no known kidney disease, and no blood in the urine. She recalls being told by another clinic two years ago that a kidney test was normal and is obtaining that report. Her parents and an infant brother died in an epidemic in her youth; no family kidney history is known. Blood pressure 164/94 (average of two readings), pulse 78, weight 70.4 kg, BMI 28.6; trace ankle swelling. Results today: sodium 139, potassium 4.6, bicarbonate 22 mmol/L; urea nitrogen 28, creatinine 1.42 mg/dL; eGFR 40 (CKD-EPI 1926 creatinine, race-free); cystatin C 1.68 mg/L, eGFR 38 (creatinine and cystatin C); urine albumin-to-creatinine ratio 240 mg/g; fasting glucose 94 mg/dL and A1c 5.6%; hemoglobin 11.2 g/dL, ferritin 168 ng/mL, transferrin saturation 24%; calcium 9.2, phosphate 3.8 mg/dL; intact PTH 84 pg/mL; 25-hydroxyvitamin D 17 ng/mL; LDL 136 mg/dL; TSH 1.9; PHQ-9 4. ECG: sinus rhythm with voltage criteria for left ventricular hypertrophy. Sent today: urinalysis with microscopy, serum protein electrophoresis with free light chains, hepatitis B, hepatitis C and HIV tests. Planned: a home blood pressure monitor for seven days, a repeat urine albumin test and a kidney ultrasound on the morning of your visit. She asks to see every result and how each was calculated. **S**

- Ida B. Wells was born enslaved on July 16, 1862, in Holly Springs, Mississippi, during the Civil War. **D**
- In the yellow fever epidemic of 1878, when she was 16, both her parents and an infant brother died; she left school and took on the care of her surviving younger siblings, teaching to support them. **D**
- She was an investigative journalist and editor who documented lynching in the United States, notably in A Red Record (1895), and campaigned against it for the rest of her life; she was also a suffragist and civil rights leader. **D**
- On June 27, 1895, she married the Chicago attorney Ferdinand L. Barnett, kept her own name alongside his, and settled in Chicago; they had four children. **D**
- She signed the call for the 1909 conference that led to the National Association for the Advancement of Colored People and is considered one of its founders, though she was left off the list of its founding committee and later drew away from it. **D**
- In 1930 she ran, unsuccessfully, for the Illinois State Senate. **D**
- She began writing her autobiography in her last years; it was published after her death as Crusade for Justice: The Autobiography of Ida B. Wells, edited by her youngest daughter, Alfreda M. Duster. **D**

2 later historical claims are omitted because they describe events after the index age. See the teaching note.

Baseline: Sodium: 139 mmol/L; Potassium: 4.6 mmol/L; Bicarbonate (total CO2): 22 mmol/L; Urea nitrogen: 28 mg/dL (high); Glucose (fasting): 94 mg/dL; Creatinine: 1.42 mg/dL (high); eGFR, creatinine (CKD-EPI 1926, race-free): 40 mL/min/1.73 m² (low); Cystatin C: 1.68 mg/L (high); eGFR, creatinine and cystatin C (CKD-EPI 1926, race-free): 38 mL/min/1.73 m² (low); Urine albumin-to-creatinine ratio: 240 mg/g (high); Hemoglobin A1c: 5.6%; Hemoglobin: 11.2 g/dL (low); Ferritin: 168 ng/mL; Transferrin saturation: 24%; Calcium: 9.2 mg/dL; Phosphate: 3.8 mg/dL; Parathyroid hormone, intact: 84 pg/mL (high); 25-hydroxyvitamin D: 17 ng/mL (low); Total cholesterol: 214 mg/dL (high); LDL cholesterol: 136 mg/dL (high); HDL cholesterol: 52 mg/dL; Triglycerides: 128 mg/dL; TSH: 1.9 mIU/L; PHQ-9: 4. All results are synthetic.

BP 164/94 mmHg; pulse 78 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 70.4 kg; BMI 28.6 kg/m². All vital signs are synthetic.

## Current medications

- Acetaminophen 500 mg oral tablet, one or two tablets up to three times a day as needed for knee aching (no more than 3,000 mg a day), in place of naproxen **S**

## Plan so far

- Confirm and stage the kidney disease: race-free eGFR from creatinine with cystatin C, repeat urine albumin-to-creatinine ratio, urinalysis with microscopy, kidney ultrasound, a monoclonal protein screen (serum protein electrophoresis and free light chains), hepatitis B, hepatitis C and HIV tests, and any earlier results she can obtain. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease (2021); New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race (2021) **S**
- Blood pressure: a validated home monitor with readings twice a day for seven days to confirm the diagnosis; sodium below 2 g a day; recheck in two weeks. Guideline: KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026) **S**
- Stop over-the-counter naproxen and use acetaminophen for knee aching; avoid all NSAIDs; tell every clinician and pharmacist about her kidneys before new medicines or contrast dye. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026) **S**
- Anemia and mineral and bone checks: hemoglobin with iron studies, calcium, phosphate, intact PTH and 25-hydroxyvitamin D at baseline. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update (2017); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026) **S**
- Baseline ECG, TSH for tiredness, a lipid panel once at diagnosis, A1c to screen for diabetes, and a PHQ-9. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023) **S**
